

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**REPORT OF FOREIGN ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2023

(Commission File No. 001-41157)

---

**BIONOMICS LIMITED**

(Translation of registrant's name into English)

---

200 Greenhill Road  
Eastwood SA 5063  
Tel: +618 8150 7400

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.  
Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):  
Yes  No

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):  
Yes  No

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  
Yes  No

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

In regard to its Annual General Meeting held in Australia on November 30, 2023, the Company advises the details of the Resolutions and the proxies received in respect of each Resolution. The Results of the Meeting is furnished herewith as an Exhibit 99.1 to this report on Form 6-K.

## EXHIBIT INDEX

Exhibit	Description
99.1	<a href="#">2023 Results of Annual General Meeting</a>

2

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

**Bionomics Limited**

(Registrant)

By: /s/ Alan Fisher

Name: Alan Fisher

Title: Chairman

Date: November 30, 2023



## Results of Annual General Meeting

ADELAIDE, Australia, and CAMBRIDGE, Mass., November 30, 2023 - Bionomics Limited (Nasdaq: BNOX) ("Bionomics" or "Company"), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need, advises the results of the Annual General Meeting held this day at 9.30 am ACDT. The attached Voting Results provides details of the proxies received and summary of votes cast for each resolution.

### FOR FURTHER INFORMATION PLEASE CONTACT:

**General**

Rajeev Chandra  
Company Secretary  
CoSec@bionomics.com.au

**Investor Relations**

Kevin Gardner  
kgardner@lifesciadvisors.com

**Investor Relations**

Chris Calabrese  
ccalabrese@lifesciadvisors.com

### About Bionomics Limited

Bionomics (NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the  $\alpha 7$  nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with MSD (known as Merck & Co., Inc., Rahway NJ, USA in the US and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions. Bionomics' pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need.

[www.bionomics.com.au](http://www.bionomics.com.au)

---

**Bionomics Limited**  
**Annual General Meeting**  
**Thursday, 30 November 2023**  
**Voting Results**

Resolution Details				Show of Hands or Poll	Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Res. Results
Resolution		Resolution Type	If s250U applies		S or P	For	Against	Proxy's Discretion	Abstain/Exclude	For	Against	Abstain
1.	Re-election of Mr Aaron Weaver as a Director of the Company	Ordinary	N/A	P	323,121,897 99.58%	726,367 0.22%	648,426 0.20%	846,530 -	323,778,055 99.78%	726,367 0.22%	846,530 -	Carried
2.	Re-election of Dr Jane Ryan as a Director of the Company	Ordinary	N/A	P	323,486,041 99.58%	721,693 0.22%	1 648,426 0.20%	487,060 -	324,142,199 99.78%	721,693 0.22%	487,060 -	Carried
3.	Re-election of Dr Errol De Souza as a Director of the Company	Ordinary	N/A	P	RESOLUTION WITHDRAWN				RESOLUTION WITHDRAWN			-

\*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

